ChAdOx1 biEBOV / University of Oxford - LARVOL DELTA

Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial. (PubMed, Lancet Microbe) - P1 | "Our results suggest that the ChAdOx1 biEBOV vaccine was safe and well tolerated. Safety and tolerability data are consistent with other vaccines using the same vaccine backbone. A single 5 × 101⁰ vp dose of the vaccine was immunogenic, generating binding antibodies against both Ebola virus and Sudan virus glycoproteins, with antibody responses boosted in the subgroup receiving a second immunisation. Future research should focus on approaches to enhance antibody responses and to elicit neutralising antibodies to Sudan virus."

Journal • P1 data • Ebola Virus Disease • Hematological Disorders • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Thrombocytopenia

A bivalent Adenovirus-Vectored Vaccine induces a robust humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus. (PubMed, J Infect Dis) - "Here, we investigated the protective efficacy of ChAdOx1-biEBOV in cynomolgus macaques using a prime or a prime-boost regimen...Viral load in blood samples and in tissue samples obtained after necropsy were not significantly different between groups. Overall, this study highlights the importance of evaluating vaccines in multiple animal models and demonstrates the importance of understanding protective efficacy in both animal models and human hosts."

Journal • Ebola Virus Disease • Infectious Disease

A Study of a New Vaccine Against Two Types of Ebola (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: University of Oxford | Recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Mar 2023 | Trial primary completion date: Dec 2022 ➔ Mar 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

A Study in Tanzania of a New Vaccine Against Two Types of Ebola (clinicaltrials.gov) - P1 | N=76 | Active, not recruiting | Sponsor: University of Oxford | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2023 ➔ Dec 2023 | Trial primary completion date: Jan 2023 ➔ Dec 2023

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease

A Study in Tanzania of a New Vaccine Against Two Types of Ebola (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: University of Oxford | Trial completion date: Jul 2022 ➔ Jan 2023 | Trial primary completion date: Jul 2022 ➔ Jan 2023

Trial completion date • Trial primary completion date • Infectious Disease

A Study of a New Vaccine Against Two Types of Ebola (clinicaltrials.gov) - P1 | N=26 | Recruiting | Sponsor: University of Oxford | Trial completion date: May 2022 ➔ Dec 2022 | Trial primary completion date: May 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date • Infectious Disease

A Study in Tanzania of a New Vaccine Against Two Types of Ebola (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: University of Oxford | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • IFNG

A Study in Tanzania of a New Vaccine Against Two Types of Ebola (clinicaltrials.gov) - P1 | N=76 | Not yet recruiting | Sponsor: University of Oxford

New P1 trial • Infectious Disease • IFNG